Capstone Investment Advisors
OTLK icon

Capstone Investment Advisors’s Outlook Therapeutics OTLK Stock Holding History

Capstone Investment Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-628
Closed -$28K – 1827
2021
Q1 		$28K Sell
628
-2,186
-78% -$83.7K ﹤0.01% 1623
2020
Q4 		$73K Buy
+2,814
New +$58.8K ﹤0.01% 1593

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.45B AUM 12.55% 1-Year Est. Return

Capstone Investment Advisors's OTLK Position: Q2 2021 in Review

Capstone Investment Advisors sold out of Outlook Therapeutics (OTLK) in Q2 2021, closing a stake of 628 shares — an estimated $28K sold.

Capstone Investment Advisors first reported a position in OTLK in Q4 2020 and held it in 2 quarters. The position peaked at $73K in Q4 2020. 63 funds tracked by Wall St. Rank hold OTLK as of Q2 2021.

  • Capstone Investment Advisors reported no remaining Outlook Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 628 Outlook Therapeutics shares in Q2 2021, an estimated $28K.
  • Capstone Investment Advisors first reported a position in Outlook Therapeutics in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's Outlook Therapeutics position peaked at $73K in Q4 2020.
  • 63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2021.

Based on Capstone Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.